However, hyperphosphatemia reduces vitamin D activity in the kidney and develops calcitriol (active metabolite of vitamin D) insufficiency that leads to defective bone mineralization and fragility, whereas hyperphosphatemia stimulates FGF-23 production in the bones [14,16,17]. The gene discussed is FGF23; the disease is hyperphosphatemia.